Eli Lilly and Company (LLY)

LLY · Health Care · United States

Eli Lilly and Company (LLY) is a company in the Health Care sector, based in United States. The stock is held in 21 ETFs we track – with its largest weight of 14.86 % in XUHL (msci-usa-health-care). Anyone holding one of these ETFs also owns a small indirect stake in Eli Lilly and Company.

Above-average ETF coverage: 21 of the 95 ETFs we cover hold Eli Lilly and Company, spread across 10 indices. That puts the stock in more ETFs than 85.2 % of the 4,334 stocks we cover.

Held in21 ETFs

Highest weight14.86 %

Indices10

SectorHealth Care

CountryUnited States

ISINUS5324571083

WKN858560

Data note 1

About Eli Lilly and Company

Eli Lilly develops and sells prescription medicines. Its fastest-growing products in recent years have been the diabetes and weight-loss treatments Mounjaro and Zepbound, both based on the active ingredient tirzepatide. Other areas include oncology, immunology and neuroscience, where the Alzheimer's treatment Kisunla received US approval in 2024. Lilly was founded in 1876 and is based in Indianapolis, Indiana.

Data note 2

Price chart

Data note 3

Performance

Performance
Year to date	+5.9 %	1 year	+48.8 %
1 month	-3.8 %	3 months	+2.3 %
Calendar year 2025	+39.2 %

52W

Data note 4

Measured in euros, Eli Lilly and Company returned +7.8 % year to date and +52.3 % over one year. The gap to the dollar figures above comes from the exchange rate alone: each daily price is converted at the ECB euro reference rate for the same day.

Data note 5

Risk metrics

Max drawdown-34.8 %

Volatility p.a.38.3 %

Data note 6

Below peak-11.1 %

Beta to S&P 5000.31

Correlation to S&P 5000.11

The close on Sep 16, 2026 was 11.1 % below the highest close since Jul 11, 2024, reached on Aug 19, 2026. Over the last 252 trading days, on days when the S&P 500 rose or fell 1 %, Eli Lilly and Company moved on average 0.31 % in the same direction. The correlation of 0.11 shows how reliable that average is: the broad market explained only a small share of the daily moves.

Data note 7

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Correlated with
Instrument	r	−1 … +1
Johnson & Johnson	+0.63
Vertex Pharmaceuticals Incorporated	+0.60
AbbVie Inc.	+0.59
Amgen Inc.	+0.54
Royalty Pharma Plc Class A	+0.53
AGLD	+0.52
Keysight Technologies Inc	-0.44
nVent Electric plc	-0.40
Broadcom Inc.	-0.37

Data note 8

Key financials

Latest reported fiscal year (FY2025, period end 2025-12-31) as filed with the SEC.

Revenue65.2 bn $

Net income20.6 bn $

Diluted EPS22.95 $

Net margin31.7 %

Return on equity77.8 %

Equity ratio23.6 %

Revenue growth+44.7 %

Revenue and profit by fiscal year
Fiscal year	Revenue	Net income	Margin
FY2023	34.1	5.2	15.4 %
FY2024	45.0	10.6	23.5 %
FY2025	65.2	20.6	31.7 %

Data note 9

Held in these ETFs

Held in these ETFs
ETF	Index	Weight	per €1,000 in the ETF
XUHL / XUHC	msci-usa-health-care	14.86 %	€148.60
SPFS	msci-world-health-care	10.96 %	€109.60
XDWH	msci-world-health-care	10.93 %	€109.30
XDEQ	msci-world-quality	2.37 %	€23.70
XD9U / XD9D	msci-usa	1.40 %	€14.00
SPYL / SPY5	sp500	1.39 %	€13.90
SXR8	sp500	1.38 %	€13.80
SWWD	msci-world	1.02 %	€10.20
SPPW	msci-world	1.02 %	€10.20
EUNL	msci-world	1.01 %	€10.10
XDWD / XDWL	msci-world	1.01 %	€10.10
WIMI	msci-world-imi	0.91 %	€9.10
SPYY	msci-acwi	0.89 %	€8.90
IUSQ	msci-acwi	0.89 %	€8.90
SPYI / SPSA	msci-acwi-imi	0.78 %	€7.80
XDEB	msci-world-minimum-volatility	0.34 %	€3.40

Data note 10

The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Eli Lilly and Company as of the fund's latest holdings list.

Weight in EUNL since 2019

Sep 30, 2019Sep 16, 2026

In EUNL, a fund tracking the MSCI World, Eli Lilly and Company had a weight of 0.24 % on Sep 30, 2019 and 1.01 % on Sep 16, 2026. Its share peaked at 1.10 % on Jun 28, 2024. The weight rises and falls with the stock's price relative to the other index members, and it also shifts when the index provider changes the composition.

Data note 11

How much Eli Lilly and Company overlaps with other holdings in a portfolio is shown by the Portfolio X-Ray and the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Eli Lilly and Company — the figure counts the ETFs holding both.

Data note 12

Key figures side by side

Key figures compared with stocks of similar ETF exposure
Stock	1 year	Volatility p.a.	Net margin	Revenue growth
Eli Lilly and Company	+48.8 %	38.3 %	31.7 %	+44.7 %
AbbVie	+21.4 %	26.9 %	6.9 %	+8.6 %
Abbott Laboratories	-22.9 %	24.1 %	14.7 %	+5.7 %
Cardinal Health	+56.7 %	26.4 %	0.7 %	-1.9 %
Cencora	+9.8 %	26.4 %	0.5 %	+9.3 %
McKesson Corporation	+28.0 %	28.6 %	1.2 %	+12.4 %
ResMed	-16.3 %	28.6 %	27.2 %	+9.8 %
Johnson & Johnson	+51.5 %	19.1 %	28.5 %	+6.0 %
Edwards Lifesciences Corporation	+18.9 %	25.1 %	17.7 %	+11.5 %

Return and volatility from our daily closing prices in US dollars; margin and growth from the latest SEC annual filing. Fiscal years do not all end on the same date.